Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.62 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.62 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.56 |
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.48 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27645860 | 0.87 | HPGDS (0.64) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL1680339 | 0.86 | PRMT5 (0.57) | HPGDSALKBH2PRMT5ADAMTS7DGAT2 | |
| SCHEMBL4903546 | 0.83 | HPGDS (0.68) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL12923053 | 0.81 | HPGDS (0.70) | HPGDSALKBH2RAB9ANPC1MAPT | |
| SCHEMBL13607996 | 0.79 | HPGDS (0.62) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL13926374 | 0.79 | HPGDS (0.62) | HPGDSALKBH2PRMT5RAB9ANPC1 | |
| SCHEMBL25910314 | 0.79 | KLKB1 (0.55) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL27150067 | 0.78 | HPGDS (0.56) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL27150069 | 0.78 | HPGDS (0.56) | HPGDSALKBH2PRMT5ADAMTS7RAB9A | |
| SCHEMBL4118702 | 0.78 | ALKBH2 (0.74) | HPGDSALKBH2RAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | HPGDS 746/4885ALKBH2 1810/4885PRMT5 1145/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | HPGDS 1307/4885ALKBH2 3731/4885PRMT5 1051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.